Deutsch English Français

Contact

EP1406855

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1406855

EP1406855 - NOVEL PROCESS FOR PREPARING RAC-BICALUTAMIDE AND ITS INTERMEDIATES [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 12.06.2009 Database last updated on 20.07.2024
Most recent event Tooltip	12.06.2009	Application deemed to be withdrawn	published on 15.07.2009 [2009/29]
Applicant(s)	For all designated states TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Pallagi út 13 4042 Debrecen / HU
	[N/P]
Former [2006/31]	For all designated states TEVA Gyógyszergyár Zártköruen Muködo Részvénytársaság Pallagi 13 4042 Debrecen / HU
Former [2005/37]	For all designated states Teva Gyogyszergyar Reszvenytarsasag Pallagi ut 13 4042 Debrecen / HU
Former [2004/16]	For all designated states BIOGAL GYOGYSZERGYAR RT. Pallagi ut 13 4042 Debrecen / HU
Inventor(s)	01 / DOLITZKY, Ben-Zion Lochamei Hagettaot 32 Petach Tikva / IL
	02 / REANY, Ofer House No. 70, Chitim Village, Lower Galilee 15280 Israel / IL
	03 / SHAMMAI, Jenny 18/2 Etzel Steet Kiryat Yam 29061 / IL
	[2004/16]
Representative(s)	Russell, Tim, et al D Young & Co LLP 120 Holborn London EC1N 2DY / GB
	[N/P]
Former [2006/48]	Russell, Tim, et al D Young & Co 120 Holborn London EC1N 2DY / GB
Former [2004/16]	Gallagher, Kirk James, et al D Young & Co, 21 New Fetter Lane London EC4A 1DA / GB
Application number, filing date	02739801.5	13.06.2002
	[2004/16]
	WO2002US18329
Priority number, date	US20010298009P	13.06.2001 Original published format: US 298009 P
	US20020371069P	09.04.2002 Original published format: US 371069 P
	[2004/16]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO02100339
	Date:	19.12.2002
	Language:	EN
	[2002/51]
	Type:	A2 Application without search report
	No.:	EP1406855
	Date:	14.04.2004
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 19.12.2002 takes the place of the publication of the European patent application.
	[2004/16]
Search report(s)	International search report - published on:	US	16.10.2003
	(Supplementary) European search report - dispatched on:	EP	02.03.2006
Classification	IPC:	C07C69/675, C07C255/49, C07C255/50, C07C317/14	[2004/16]
	CPC:	C07D301/14 (EP,US); C07C255/58 (EP,US); C07C315/04 (EP,US); C07C317/14 (EP,US); C07C319/14 (EP,US)
	C-Set:	C07C315/04, C07C317/46 (EP,US); C07C319/14, C07C323/52 (US,EP)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2004/16]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	NEUES VERFAHREN ZUR HERSTELLUNG VON RAC-BICALUTAMID UND DESSEN ZWISCHENPRODUKTEN	[2004/16]
	English:	NOVEL PROCESS FOR PREPARING RAC-BICALUTAMIDE AND ITS INTERMEDIATES	[2004/16]
	French:	NOUVEAU PROCEDE POUR LA PREPARATION DE RAC-BICALUTAMIDE ET DES PRODUITS INTERMEDIAIRES DE CELUI-CI	[2004/16]
Entry into regional phase	13.01.2004	National basic fee paid
	13.01.2004	Search fee paid
	13.01.2004	Designation fee(s) paid
	13.01.2004	Examination fee paid
Examination procedure	08.01.2003	Request for preliminary examination filed International Preliminary Examining Authority: US
	13.01.2004	Examination requested [2004/16]
	24.03.2006	Observations by third parties
	18.05.2006	Observations by third parties
	26.05.2006	Observations by third parties
	11.10.2006	Despatch of a communication from the examining division (Time limit: M06)
	11.04.2007	Reply to a communication from the examining division
	17.06.2008	Despatch of a communication from the examining division (Time limit: M06)
	30.12.2008	Application deemed to be withdrawn, date of legal effect [2009/29]
	13.02.2009	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2009/29]
Fees paid	Renewal fee
	01.06.2004	Renewal fee patent year 03
	13.06.2005	Renewal fee patent year 04
	12.06.2006	Renewal fee patent year 05
	14.06.2007	Renewal fee patent year 06
	25.03.2008	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[DA]WO0100608 (RICHTER GEDEON VEGYESZET [HU], et al) [DA] 20-26 * the whole document *;
		[E]WO02053138 (SHANAHAN-PRENDERGAST ELISABETH [IE]) [E] 44-49* claim 9 ( page 43, line 23 ); claim 15; claim 52 ( page 60, line 14 ); claim 58 *;
		[A] - FOURNIER J.-P. ET AL, "(Hydroxy-2-alkyl)- et (hydroxy-3-alkyl)-phénylsulfones à activité hypolipidémiante", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, (1982), vol. 17, no. 1, ISSN 0223-5234, pages 53 - 58, XP002968407 [A] 1-12 * pages 53 and 54, paragraph 2.1.1 *
		[A] - ARIAS L.A. ET AL., "Synthesis of functionalized cyclic enamines from lithium alkylphenyl sulfones and N-carbo-tert-butoxy lactams", JOURNAL OF HETEROCYCLIC CHEMISTRY., US HETEROCORPORATION. PROVO., (200102), vol. 38, no. 1, pages 29 - 33, XP002354245 [A] 1-7 * page 29, left-hand column: results and discussion; page 30, scheme I, compound of formula 4 * DOI: http://dx.doi.org/10.1002/jhet.5570380104
		[A] - LI Z. ET AL, "Syntheses of titanium mu-arylimido and mu-pyridylimido complexes bearing (un)substituted cyclopentadienyl ligand", JOURNAL OF ORGANOMETALLIC CHEMISTRY, ELSEVIER-SEQUOIA S.A. LAUSANNE, CH, (20000402), vol. 598, no. 2, ISSN 0022-328X, pages 339 - 347, XP004193190 [A] 13-19 * experimental, paragraphs 4.2, 4.9 and 4,12 * DOI: http://dx.doi.org/10.1016/S0022-328X(99)00732-9
		[A] - TUCKER H. ET AL., "Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides", JOURNAL OF MEDICINAL CHEMISTRY., US AMERICAN CHEMICAL SOCIETY. WASHINGTON., (1988), vol. 31, no. 5, pages 954 - 959, XP002353070 [A] 20-26 * the whole document * DOI: http://dx.doi.org/10.1021/jm00400a011
		[DA] - LIEBERMAN HERBERT A., Pharmaceutical Dosage Forms: Tablets vol. 2 (2nd. ed.), NEW YORK, MARCEL DEKKER, INC., (1990), XP008059470 [DA] 44-49 * pages 107-200 *
	International search	[A]US4554381 (DESBOIS MICHEL [FR]);
		[A]US5723485 (GUENGOER TIMUR [FR], et al);
		WO9839326 [ ] (MONSANTO CO [US], et al);
		WO9749679 [ ] (ONO PHARMACEUTICAL CO [JP], et al);
		EP1158359 [ ] (EASTMAN KODAK CO [US]);
		[A]US3254094 (ROSS STEPHEN T);
		DE2537288 [ ] (BAYER AG);
		[A]US4636505 (TUCKER HOWARD [GB]);
		DE4218765 [ ] (BASF AG [DE]);
		WO0128990 [ ] (NOBEX CORP [US], et al)
		[A] - FRESKOS ET AL., "Preparation of aromatic sulfonyl alpha, -hydroxy hydroxamic acid compounds as matrix metalloprotease inhibitors", CAPLUS, Database accession no. 1998-612095, XP002965452
		[A] - TAKAHASHI ET AL., "Preparation and formulation of aryl sulfides, sulfoxides and sulfones as matrix metalloproteinases inhibitors", CAPLUS, Database accession no. 1998-42377, XP002966180
		[A] - SLUSAREK ET AL., "Color photographic thermally processable film comprising blocked developer compound", CAPLUS, Database accession no. 2001-867994, XP002965454
		[A] - BUETTNER ET AL., "Trifluoromethyl-substituted aminobrenzonitriles", CAPLUS, Database accession no. 1977-171116, XP002966181
		[A] - TUCKER ET AL., "Resolution of the non-sterodial antiandrogen 4'-(cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-trifluoromethyl)propionanilide and the determination of the absolute configuration of the active enantiomer", CAPLUS, Database accession no. 1988-150026, XP002966182
		[ ] - J. MED. CHEM., (1988), vol. 31, no. 4, pages 885 - 887
		[AP] - JAMES ET AL., "A two step synthesis of the anti-cancer drug (R,S)-bicalutamide", CAPLUS, Database accession no. 2002:414656, XP002966183
		[ ] - SYNTHESIS, (2002), no. 7, pages 850 - 852
		[A] - VON LOCQUENGHIEN HORCHLER ET AL., "Preparation of oxiranecarboxylates and analogs", CAPLUS, Database accession no. 1994-191513, XP002966184
		[A] - RASTETTER ET AL., "3,5-Dinitroperoxybenzoic acid. A crystalline storable substitute for peroxytrifluoroacetic acid", CAPLUS, Database accession no. 1978-490113, XP002966185
		[ ] - J. ORG. CHEM., (1978), vol. 43, no. 16, pages 3163 - 3166
		[A] - EKWURIBE N., "Asymmetric synthesis and antiandrogenic use of enantiomers of casodex (bicalutamide) and derivatives from enantiomers of citramalic acid or proline", CAPLUS, Database accession no. 2001-300671, XP002966186
	other	EP0100172
		WO9310782
		US6123956
		WO0101960
		- ABDOU H.M. ET AL., "Dissolution", ABDOU H.M. ET AL., GENNARO A.R. ET AL., Remington: the science and practice of pharmacy (chapter 35), 20th edition, INDIA AT GOPSONS PAPERS LTD., NOIDA, PINCOTT WILLIAMS AND WILKINS, (2000), pages 654 - 666, ISBN 0-7817-200X-4, XP002994171
		- HOENER B-A., BENET L.Z., "Factors influencing drug absorption and drug availability", HOENER B-A., BENET L.Z., BANKER G.S., RHODES C.T., Modern pharmaceutics, 2nd ed., USA, MARCEL DEKKER, INC., (1990), pages 143 - 180, ISBN 0-8247-7499-X, XP002994172
		- "SUMMARY BASIS OF APPROVAL (SBOA) OF NDA 20-498 FOR BICALUTAMIDE 50-MG TABLET (CASODEX)", NDA SUBMITTED BY ASTRA ZENECA FOR BICALUTAMIDE, XX, XX, XX, (19940914), no. 20498, pages 1 - 22, XP002994183
		- COCKSHOTT I.D. ET AL., "The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing", EUR UROL, (1990), vol. 18, no. SUPPL.3, pages 10 - 17, XP008065131
		- "Search results from the "OB_Rx" table for query on "020498"", ORANGE BOOK ONLINE, page 1, URL: http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020498&..., XP002997829
		- "bicalutamide (1247)", BUDAVARI S. ET AL., The Merck Index, 12th ed., NJ, MERCK RESEARCH LABORATORIES, (1996), pages 201 - 202, XP002997830
		- MCKILLOP D. ET AL., "Enzyme-inducing effects of bicalutamide in mouse, rat and dog", XENOBIOTICA, (1998), vol. 28, no. 5, pages 465 - 478, XP002997831 DOI: http://dx.doi.org/10.1080/004982598239399
		- KOLVENBAG GJCM ET AL., "Receptor affinity and potency of non-steroidal antiandrogens: translation of preclincal findings into clinical activity", PROSTATE CANCER AND PROSTATIC DISEASES, (1998), vol. 1, pages 307 - 314, XP002997832 DOI: http://dx.doi.org/10.1038/sj.pcan.4500262
		- RADIATION THERAPY ONCOLOGY GROUP, "Phase III trial of radiation therapy with or without casodex in patients with PSA elevation following radical prostatectomy for pT3N0 carcinoma of the prostate", PROTOCOL RTOG 96-01, (20000905), pages 1 - 34 (+COVER, INDEX, AND ELIGIBILITY CHECK), XP002997833
		- NEKTAR TRANSFORMING THERAPEUTICS, "glossary of terms", INET EXTRACT OF PHARMACEUTICAL CO NEKTAR, page 2 PG-S, URL: http://www.nektar.com/wt/page/glossary, XP002997834
		- MICROCHEM, "Processing", INET EXTRACT OF CO MICROCHEM, page 1, XP002997835
		- "Bicalutamide is a non-steroidal antiandrogen, developed by AstraZeneca", PHAR, Database accession no. 26650, XP002997836
		- ANSEL H.C. ET AL., Pharmaceutical dosage forms and drug delivery systems, 6th ed., WILLIAMS AND WILKINS, (1995), XP002997837

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p